Default Category
-
Shenzhen Capital Group
Gompers, Paul A.; Chen, Shaohui; Lin, Jessie; Ling, ShelleyCase HBS-211029-EFinanceHaitao Jin, Chairman of Shenzhen Capital Group Co., Ltd. ("SCGC") and Wanshou Li, President of the SCGC must decide how to continue to grow their venture capital/private equity firm in China. SCGC is a premier VC/PE fund in China and a pioneer of the Government Sponsored Fund (GBF) structure. The firm had grown to RMB 20 billion in just ten years and had funds in 29 different cities across China. As competition for investments becomes more intens...Starting at €8.20
-
The Abraaj Group and the Acibadem Healthcare Investment (A)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214021-EFinanceThis case concerns the proposed buyout of Acibadem, a leading hospital chain in Turkey. Abraaj, a MENA region private equity firm, proposes to make its first investment in Turkey. The case highlights the role of Turkish health care reform in driving the value. The case provides an opportunity to estimate the potential return on investment as well as evaluate the structuring of the transaction.Starting at €8.20
-
Advantage Partners: Dia Kanri (A)
Gompers, Paul A.; Sato, Nobuo; Kanno, AkikoCase HBS-214016-EFinanceThis case explores the opportunity to purchase the condominium management business of a distressed real estate developer by Advantage Partners, a leading Japanese private equity firm. The case explores investment structuring, bidding strategy, and the ability of private equity firms to add value. The role of private equity in Japan is also explored and allows students to compare the Japanese merger and acquisition market to the U.S. and Europe.Starting at €8.20
-
Advantage Partners: Dia Kanri (B)
Gompers, Paul A.; Sato, Nobuo; Kanno, AkikoCase HBS-214017-EFinanceThis case presents the final decision and outcomes for the (A) case.Starting at €5.74
-
The Abraaj Group and the Acibadem Healthcare Investment (B)
Gompers, Paul A.; Uluduz, Bora; Abacioglu, FirdevsCase HBS-214022-EFinanceThis case provides an update on the ultimate outcome of the transaction presented in The Abraaj Group and the Acibadem Healthcare Investment (A).Starting at €5.74